Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLBS 12

Next Previous
Search
Drug Profile

CLBS 12

Alternative Names: Autologous CD34+ cells - Lisata Therapeutics; CLBS-12; HONEDRA; LSTA-12

Latest Information Update: 25 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Caladrius Biosciences
  • Developer Lisata Therapeutics
  • Class Haematopoietic stem cells therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thromboangiitis obliterans
  • New Molecular Entity No
  • Available For Licensing Yes - Peripheral ischaemia

Highest Development Phases

  • Phase II Chronic limb-threatening ischemia

Most Recent Events

  • 25 Apr 2023 Lisata therapeutics plans for pre-JNDA consultation with the Pharmaceuticals and Medical Devices Agency (PMDA) by Q4 2024
  • 30 Mar 2023 Lisata therapeutics plans for formal clinical consultation with the Pharmaceuticals and Medical Devices Agency (PMDA) by 2023
  • 07 Dec 2022 Phase II development is ongoing in Japan (IM) (JapicCTI-173750) (NCT02501018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top